Survodutide peptide(tseem hu ua BI 456906) yog GLP-1/glucagon (GCGR) dual receptor agonist peptide nrog ntev - ua lipotropic tsim, tsim nyog rau kev tshawb fawb txog kev siv tshuaj ib zaug ib lim piam.
Cov khoom no txhim kho satiety, txo cov zaub mov kom tsawg, thiab ua rau lub plab zom mov los ntawm txoj kev GLP-1, thaum tib lub sijhawm nce kev siv hluav taws xob thiab ua rau cov kab mob siab metabolic (gluconeogenesis, lipolysis, thiab lwm yam) los ntawm txoj kev glucagon. Cov nyhuv synergistic ntawm ob txoj hauv kev no ua rau muaj peev xwm ntau dua rau kev poob phaus thiab cov txiaj ntsig ntawm cov kab mob siab metabolic.
Shaanxi Medibridge tau mob siab rau muab siab -purity custom peptide synthesis cov kev pabcuam rau cov tsev kawm tshawb fawb, tsev kho mob, thiab tsev kawm qib siab. Peb muaj ntau tshaj 14 xyoo ntawm kev paub nyob rau hauv peptide kev tshawb fawb thiab synthesis. Yog tias koj tab tom nrhiav rau lub chaw tsim khoom peptide txhim khu kev qha, thov hu rau Shaanxi Medibridge Biotech Co., Ltd.
COA
|
Yam khoom |
Txuj |
Cov txiaj ntsig |
|
Purity |
Ntau dua lossis sib npaug li 98% |
99.78% |
|
Peptide Assay |
Ntau dua lossis sib npaug li 80% |
90.35% |
|
Loj Spectrum |
4231.69 |
4231.69 |
|
Qhov tshwm sim |
Dawb hmoov |
Ua raws |
|
Solubility |
Soluble hauv dej |
Ua raws |
|
Clarity thiab xim ntawm kev daws |
Ntshiab thiab tsis muaj xim |
Ua raws |
|
Sodium ion |
Tsawg dua lossis sib npaug li 3.0% |
1.33% |
|
Dej |
Tsawg dua lossis sib npaug li 10.0% |
1.09% |
|
Residual Solvent: |
||
|
Methanol |
Tsawg dua lossis sib npaug li 0.3% |
0.0049% |
|
Isopropanol Acetonitrile |
Tsawg dua lossis sib npaug li 0.5% |
N.D. |
|
Methanol |
Tsawg dua lossis sib npaug li 0.041% |
0.029% |
|
Methylene Chloride |
Tsawg dua lossis sib npaug li 0.06% |
0.015% |
|
N,N{0}}Dimethylformamide |
Tsawg dua lossis sib npaug li 0.088% |
0.054% |
|
Triethylamine |
Tsawg dua lossis sib npaug li 0.032% |
N.D. |
|
Tert -butyl methyl ether |
Tsawg dua lossis sib npaug li 0.5% |
0.17% |
|
Endotoxin |
Tsawg dua lossis sib npaug li 5 EU / mg |
0.5 EU / mg |
|
Microbial Txwv |
Tag nrho cov kab mob aerobic<100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Cia |
Khaws rau hauv qhov chaw tsaus thiab txias qhuav (-20 txog 8 degree) |
|
|
|
||
Specifications (rau kev tshawb fawb siv nkaus xwb)
|
Daim ntawv |
Qauv Order |
Specification |
|
Cov hmoov nyoos |
1 g |
Purity yog NLT 99.75% |
|
Vials |
10 vials |
3ml / 5ml / 7ml / 15ml vials thiab lwm yam. |
Mechanism ntawm kev txiav txim ntawm Survodutide
Lub dual -receptor synergy ua "ob lub levers, ib qho kev taw qhia." GLP-1R yog lub luag haujlwm rau inhibiting kev noj zaub mov, ncua kev ua pa hauv plab, txhim kho pancreatic - cell function, thiab inhibiting -cell glucagon secretion; GCGR nyob rau hauv daim siab txhim kho fatty acid oxidation, txhawb lub siab lipid mobilization, thiab nce zog siv zog.
Ob txoj hauv kev no ua haujlwm sib koom ua ke kom txo qhov hnyav thiab txhim kho daim siab metabolism. GLP-1's "tswj kom tsawg thiab stabilizing qabzib" ntxiv rau glucagon's "kev siv nyiaj ntau ntxiv thiab tshem tawm cov rog rog," tsis yog tsuas yog poob phaus tab sis kuj tseem tiv thaiv cov kab mob rog rog thiab fibrosis.
Cov Lus Qhia Tseem Ceeb Kev Tshawb Fawb thiab Kev Tshawb Fawb Txog Kev Tshawb Fawb (Rau Kev Sib Pauv Kev Kawm Tsuas)
1. Receptor Pharmacology thiab Signal Transduction
Hauv vitro platforms thiab nyeem ntawv
a. cAMP kinetics: HEK293/CHO stably transfected tib neeg GLP-1R thiab GCGR, HTRF/GloSensor tiag- lub sij hawm nkhaus, kev tsim cov concentration-effect thiab lub sij hawm-ffect plots; Kev ntsuas sib npaug hauv qab 0% thiab 2-10% tib neeg cov ntshav / cov kab mob albumin los ntsuas qhov kev hloov pauv ntawm cov lipotropic peptides ntev.
b. -arrestin recruitment and receptor endocytosis: BRET/PathHunter los yog fluorescently labeled receptor (SNAP-tag) live-cell imaging to comparison the recruitment amplitude, half-time, and recycling rate of GLP-1R and GCCR.
c. Txoj kev hauv qab: pCREB/pERK/pAKT Western blot lossis AlphaLISA; nuclear translocation imaging (CREB/FOXO).
d. Kev Ntsuas Kev Ntsuas: Xam txheeb txheeb ze siv Emax / EC50 ntsuas ntawm tib lub platform lossis raws li tus qauv tsim (piv txwv li, Dub-Leff/ΔΔlog(τ/KA)) los sib piv GLP-1R monoagonals nrog glucagon.
Cov Ntsiab Cai Tswj
a. Zoo: Semaglutide (GLP-1R), Glucagon (GCGR); Combined Controls: "yooj yim superposition" ntawm qhov sib npaug ntawm qhov ntau thiab tsawg vs. Survodutide.
b. Thaiv: Exendin (9-39) (GLP-1R antagonist), me me molecule/peptide GCGR antagonists; CRISPR/siRNA receptor silencing.
Kev txiav txim siab
a. Ntev - ua yeeb yam lipotropic peptides nkag mus rau hauv cov yas; qis-cov khoom siv adsorption + 0.05–0.1% BSA tuaj yeem txhim kho kev tsim tawm ntau dua.
b. Qhov tsis yog -cov cim qhia ntawm Gq/ -arrestin rau GCGR tuaj yeem tshawb nrhiav, tab sis kev cia siab ntawm lub cev thiab qhov cuam tshuam ntawm lub cev yuav tsum raug sau tseg.
2. Lub siab Metabolism thiab MASH/NASH
Hauv Phase II txoj kev tshawb fawb tau nthuav tawm ntawm EASL 2024 thiab luam tawm ib txhij hauv NEJM,Survodutide peptidetau ntsib nws thawj qhov kawg: nyob rau lub lim tiam 48, qhov feem pua ntawm cov neeg mob uas muaj kev txhim kho MASH thiab tsis muaj mob fibrosis yog 83% (piv rau 18.2% hauv pawg tswj).
Hauv Vitro / Organoid Qauv
a. Tib neeg tus qauv hepatocyte/hepatic organoid lipotoxicity qauv (OA/PA induction): Roj Liab O/BODIPY, cellular TG, p-ACC, thiab lipid metabolism transcriptome (SREBP1c/FASN/SCD1, CPT1A/ACOX1/PPAR, FGF21).
b. Kupffer cell-hepatocyte-stellate cell triple co- kab lis kev cai: Lipotoxicity + TGF- stimulation, kev soj ntsuam qhov mob (TNF- /IL-1 /CCL2), fibrosis (COL1A1/ {{13}1}, hydrocrosis thiab TIMP) media).
Tsiaj Qauv
a. Fibrosis qauv xws li WD+fructose, CDAHFD, los yog AMLN/Gubra-NASH: Kev ntsuam xyuas qhov muag tsis pom kev siv MRI-PDFF, daim siab TG, NAS/SAF cov qhab nia, Sirius Red quantification, thiab thib ob harmonic imaging; ALT / AST, cov kua tsib acid profile, thiab FGF21.
b. Endpoint stratification: Sib txawv ntawm kev koom tes rau "anti-steatodegeneration" thiab "anti-fibrosis"; Kev tshuaj xyuas qhov ua tau zoo gradient ntawm F2-F3 pawg pab pawg kawg.
Kev sim siab
a. Kev sib koom ua khub- hnyav lossis khub- pub pab pawg los ntsuas qhov cuam tshuam ncaj qha rau lub siab ntawm "tshaj qhov poob phaus."
b. Tsim lub kaw- lub voj voog los ntawm kev sib txuas cov kua tsib kua qaub-FXR/TGR5 cov cim nrog hepatic mitochondrial muaj nuj nqi.
Cov Lus Qhia Ntxiv Ntxiv (Rau Kev Tshawb Fawb Txog Kev Tshawb Fawb thiab Kev Tshawb Fawb nkaus xwb)
1. Kev ntsuam xyuas hauv vitro yuav tsum ua kom zoo nyob rau hauv cov xwm txheej uas muaj 0.1% HSA / BSA, thiab qhov ua tau zoo sib txawv nrog / tsis muaj ntshav qab zib yuav tsum tau tshaj tawm kom tsis txhob muaj qhov ua tau zoo tshaj.
2. Hauv kev sim tsiaj, qeeb titration nrog kev tswj hwm txhua lub lim tiam yog nyiam; Kev sib koom ua ke pub noj los yog cov kab mob sib txuas ua ke tuaj yeem txhim kho lub zog ntawm kev ntxub ntxaug rau cov kab mob siab ncaj qha.
3. Nyob rau theem receptor, cov yam ntxwv ntawm lub hauv paus (qib qhia tawm, kev sib txuas ntawm lub peev xwm, endocytic kinetics) ntawm GLP-1R/GCGR dual txoj kev yuav tsum tau muab los muab keeb kwm yav dhau los rau kev tsom xam kev tsis ncaj ncees ntawm cov nqaij mos.
4. Sau thiab tshaj tawm cov ntsiab lus kam rau siab xws li xeev siab/pas plab khoob kom pab txhawb ntxiv rau kev kawm ntev -.
FAQ
Q: Yuav ua li cas yog dissolving nyuaj?
A: Ua ntej, ntub nrog ib qho me me ntawm DMSO, tom qab ntawd ntxiv PBS uas muaj 0.1% BSA rau kev dilution stepwise; yog tias tsim nyog, maj mam sonicate los yog vortex sib tov, tsis txhob muaj zog nplawm thiab foaming.
Q: Loj adsorption poob ntawm tsawg concentration?
A: Ntxiv 0.05–0.1% carrier protein los yog 0.01% Tween-20 (ua pov thawj biocompatibility ua ntej), thiab siv cov khoom siv uas tsis tshua muaj adsorption.
Q: Puas tuaj yeem tswj xyuas qhov sib xws ntawm cov khoom siv?
A: Qhov purity sib txawv ntawm cov khoom sib txawv ntawm cov khoom yog ± 0.005%.
Q: Koj puas muab cov lus qhia txog kev tswj lossis kev sib xyaw ua ke?
A: Peb tuaj yeem muab cov qauv kev tswj hwm zoo sib xws / sib txawv thiab cov txheej txheem kev sim cov txheej txheem los ua kom tau raws li qhov xav tau ntawm cov txheej txheem, kev ua tau zoo, thiab kev ntsuas kev sib xyaw ua ke.
Q: Koj puas yog Survodutide peptide chaw tsim tshuaj paus?
A: Yog, peb yog ib qho ntawm 7 GMP - tswj peptide manufacturers hauv Suav teb.
Cim npe nrov: Tuam Tshoj survodutide peptide manufacturers, lwm tus neeg, Hoobkas
